AstraZeneca on Thursday released its fourth-quarter and full-year financial results, touting 6% total revenue growth for 2023 even as its COVID-19 business plummeted by more than 90%.
Tag Archive for: Beyfortus
The drug makers co-developed the RSV shot for infants and toddlers called Beyfortus, which has already been approved for use in the European Union and United States.
Manufacturers of RSV immunizations will make an additional 230,000 doses available for infants in January, the White House said on Thursday, after U.S. government officials met with suppliers to discuss meeting demand during winter.
White House officials on Tuesday met with representatives of Sanofi, AstraZeneca, and Thermo Fisher “and urged them to work expeditiously to meet demand for immunizations this winter season through the commercial market,” the White House said in a statement.
In an R&D event on Thursday, the French pharma is trying to win over its investors by highlighting a dozen potential blockbusters and charting strong growth for the company through 2030.
The additional doses, which the CDC said will be distributed immediately to physicians and hospitals, will help improve the availability of the drug at a time when a surge in cases of the disease is outpacing supply.
The company said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in infants and toddlers, as a surge of cases is outpacing supply.
The therapy, branded as Beyfortus, will be available in the U.S. ahead of the upcoming 2023-24 RSV season, Sanofi said.
Sanofi’s global head of R&D, John Reed, is leaving his position to pursue another opportunity outside the company, the French multinational announced Monday.
The European Commission has approved Sanofi and AstraZeneca’s Beyfortus for the prevention of a common and highly contagious type of respiratory infection in infants.
